Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

22 29 90 108

Gross margin 245 88 490 600

Operating expenses:

Research and development 1,247 6,164 13,491 28,064

Selling, general and

administrative 3,995 6,040 16,865 25,152

Provision for settlement of

litigation (1,640) 5,280 (4,240) 5,280

Write-off of prepaid royalty - 1,268 - 1,268

Total operating expenses 3,602 18,752 26,116 59,764

Other income 139 431 836 1,454

Net loss before income tax benefit (3,218) (18,233) (24,790) (57,710)

Income tax benefit 1,470 929 1,470 929

Net loss $ (1,748) $(17,304) $(23,320) $(56,781)

Net loss per basic and diluted

share $ (0.06) $ (0.68) $ (0.79) $ (2.52)

Shares used in computing basic and

diluted net loss per share

(adjusted for 1-for-6 reverse

stock split on July 13, 2007) 30,621 25,621 29,621 22,553

Selected Condensed Consolidated Balance Sheet Data

(Unaudited)

December 31 December 31

2007 2006

Cash, cash equivalents and

marketable securities $ 7,813 $ 29,496

Working capital 877 12,682

Total assets 29,293 51,778

Total stockholders' equity 2,931 14,642


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...and ST. LOUIS, Nov. 29 VIDA Diagno... software for the advanced analysis of pulmonary d...in minimally invasive delivery of interventional o...gned a definitive agreement covering joint develop...igation and biopsy system. ,, "Veran,s innovat...
(Date:11/29/2009)...RNewswire/ -- Stimulated by the ten years of Synap...al Systems USA announced today, at the Radiologica...the formation of its Medical Informatics Division...roup will integrate all functions associated with ...latform for future growth. ,, Several organizat...
(Date:11/28/2009)... Siemens Healthcare redefines prod...(Total imaging matrix) technology and with its new...technologies are introduced in the new MAGNETOM &#...ra* 3T scanners at the 95th Scientific Assembly an...rth America (RSNA) from November 29 to December 3 ...
Breaking Medicine Technology:VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 2VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 3VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System 4FUJIFILM Establishes Medical Informatics Organization 2FUJIFILM Establishes Medical Informatics Organization 3Siemens Introduces Its New Power Couple at RSNA 2009 2Siemens Introduces Its New Power Couple at RSNA 2009 3Siemens Introduces Its New Power Couple at RSNA 2009 4Siemens Introduces Its New Power Couple at RSNA 2009 5Siemens Introduces Its New Power Couple at RSNA 2009 6Siemens Introduces Its New Power Couple at RSNA 2009 7Systems thinking and the obesity debate 10705 1Faithful mothers have healthier babies 10703 1Cornell Researchers Identify a Weak Link in Cancer Cell Armor 61240 1Cornell Researchers Identify a Weak Link in Cancer Cell Armor 61240 2
...a From 741-patient Trial Show Those Treated with L...t on Blood Pressure Compared,to Ibuprofen, EAST HA...s with,osteoarthritis who also have controlled hyp... daily blood pressure when treated with,the invest...mpared,to a slight increase in those taking ibupro...
...N, Pa., June 15, 2007 /PRNewswire/ -- Solstice,Neu...from a,multicenter, forced dose escalation study o...loc(R)) recently presented at the 11th,Internation...stanbul, Turkey. , This was the first multicenter ...calating treatment doses of 10,000 Units, 12,500,U...
Other Medicine Technology:Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 2Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 3Solstice Neurosciences Presents Escalating Dose Study at,International Congress in Istanbul, Turkey 4
(Date:11/29/2009)... "The YogaForce A-Line Athletic Mat is grea... Weil, M.D., author and physician best known for e...ive medicine. Go to www.yogaforce.com and order...ift list. , San Francisco... the holidays, the YogaForce newly patented, revol...
(Date:11/28/2009)...Nov. 28 Get ready for advanced ...nical routine when Siemens introduces syngo...nnual Meeting of the Radiological Society of North...McCormick Place (Booth #825, East Building/Lakesid... , Siemens, new imaging software for multimodal...
(Date:11/28/2009)...elp lift spirits, recognize signs of depression ,...For many seniors, the holiday season can trigger m...uggle with health issues or worry about money prob.... , To help overcome the seasonal blues, the AG...ing advice: , Get out and socialize or invite fa...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today issued its la...c data. It shows that the lethality of the virus ... the virus,s current outbreak in the spring of 200...(s.d. 0.1). The H1N1 infectivity count, however, r...n (PRWEB) November 27, 2009 -- Biotech firm Replik...
(Date:11/27/2009)...N.Y., Nov. 27 Preventin...r and fortunately every year, new vaccines are bei...ll vaccines boost immunity for the same period of ...ots, needed to keep immunity strong? ,, In th... American Academy of Pediatrics, Michael Pichicher...
Breaking Medicine News(10 mins):Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3
...nsion journal suggests that increasing, dietary ...revention of hypertension, a major pu...e good sources of potassium and low in sodium ...Hypertension,concludes that an increase in potassi...
...olecular "smart bombs" to target metastasis with a...ficantly lower doses of toxic chemotherapy, with l...ding to a collaborative team of researchers at the...ector of Translational Research David Cheresh, Ph....
...ty HealthSystem,Consortium (UHC), welcomes Susan K...Chief Learning Officer. Dr. Pingleton has more tha...cine and comes to UHC from The,University of Kansa... Scholar in Residence at the Association of,Americ...
...sk for psychiatric disorders, study finds , ...lone isn,t associated with an increased risk of me...en suggested that pregnant women and those who,ve ...he study. , To determine whether this was true, th...
... trusted and,accessible health care providers, pha... and make more than 80 million recommendations to ...tients will follow these,recommendations. In fact,... purchase a particular OTC medicine based on,their...
...ny,(Nasdaq: PRGO ;TASE) announced today that Jose...t at the Oppenheimer & Co. Inc. 8th Annual Consume...m. (ET) at the Four Seasons,Hotel in Boston. The p...l healthcare supplier that develops,manufactures a...
Other Medicine News:Health News:Unilever Unveils Promise(R) SuperShots(R) for Blood Pressure, the First Functional Shot to Increase Daily Potassium Intake to Help Reduce the Risk of High Blood Pressure 2Health News:Unilever Unveils Promise(R) SuperShots(R) for Blood Pressure, the First Functional Shot to Increase Daily Potassium Intake to Help Reduce the Risk of High Blood Pressure 3Health News:Unilever Unveils Promise(R) SuperShots(R) for Blood Pressure, the First Functional Shot to Increase Daily Potassium Intake to Help Reduce the Risk of High Blood Pressure 4Health News:Unilever Unveils Promise(R) SuperShots(R) for Blood Pressure, the First Functional Shot to Increase Daily Potassium Intake to Help Reduce the Risk of High Blood Pressure 5Health News:'Smart bomb' nanoparticle strategy impacts metastasis 2Health News:University HealthSystem Consortium Names Susan K. Pingleton, MD, as Its Chief Learning Officer 2Health News:Pregnancy Alone Not A Risk for Mental Health Problems 2
Ovation BioNatural Pipette, one-stroke, fixed volume, 300L
...nd value!, Comfortable feel and less hand fatigue...rol while pipetting with smooth, light plunger spr...ntamination and sterilization without the need for... for reproducible, accurate volume settings , Acc...
Pipetman F400
...Pipette is a synonym for pipetting accuracy, a smo...ior operating comfort. Its single, multifunctional...d blow-out as well as eject the tip. Product featu...accuracy and precision. Ejection sleeve can be rem...
Medicine Products: